SHC (Sotera Health Company Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Michael B. Petras Jr. | Executive Chairman | Sell | — | — |
| 2026-08-11 | Michael P Rutz | President of Sterigenics | Sell | — | — |
| 2026-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | — | — |
| 2026-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | — | — |
| 2026-05-27 | David E. Wheadon | Director | A | — | — |
| 2026-05-27 | Christopher Simon | Director | A | — | — |
| 2026-05-27 | Ruoxi Chen | Director | A | — | — |
| 2026-05-27 | VINCENT K PETRELLA | Director | A | — | — |
| 2026-05-27 | James Neary | Director | A | — | — |
| 2026-05-27 | Karen Flynn | Director | A | — | — |
| 2026-05-27 | SEAN LAURENCE CUNNINGHAM | Director | A | — | — |
| 2026-05-27 | Kenneth D. Krause | Director | A | — | — |
| 2026-05-27 | Richard G Kyle | Director | A | — | — |
| 2026-05-27 | ALTON SHADER | Chief Executive Officer | A | — | — |
| 2026-05-27 | Ann R. Klee | Director | A | — | — |
| 2026-05-15 | GTCR FUND XI/A LP | Director | Sell | — | — |
| 2026-05-15 | Warburg Pincus XI Partners, L.P. | Director | Sell | — | — |
| 2026-05-15 | WARBURG PINCUS LLC | Director | Sell | — | — |
| 2026-04-02 | ALEXANDER DIMITRIEF | Former SVP, GC and Sec. | F | — | — |
| 2026-03-10 | GTCR CO-INVEST XI LP | Director | Sell | — | — |
| 2026-03-10 | Warburg Pincus XI, L.P. | Director | Sell | — | — |
| 2026-03-10 | Warburg Pincus Partners GP LLC | Director | Sell | — | — |
| 2026-03-04 | Michael P Rutz | President of Sterigenics | MIXED | — | — |
| 2026-03-04 | Jonathan M. Lyons | Sr. Vice President, CFO | MIXED | — | — |
| 2026-03-04 | ALEXANDER DIMITRIEF | SVP, General Counsel and Sec. | MIXED | — | — |
| 2026-03-04 | Michael B. Petras Jr. | Chairman & CEO | MIXED | — | — |
| 2026-02-13 | Richard G Kyle | Director | — | — | — |
| 2025-12-10 | Michael B. Petras Jr. | Chairman & CEO | Sell | — | — |
| 2025-12-05 | GTCR FUND XI/A LP | Director | Sell | — | — |
| 2025-12-05 | Warburg Pincus XI-C, LLC | Director | Sell | — | — |
| 2025-12-05 | Warburg Pincus Partners GP LLC | Director | Sell | — | — |
| 2025-11-12 | Warburg Pincus XI Partners, L.P. | Director | Sell | — | — |
| 2025-11-12 | Warburg Pincus XI-C, LLC | Director | Sell | — | — |
| 2025-11-12 | GTCR FUND XI/C LP | Director | Sell | — | — |
| 2025-09-09 | GTCR CO-INVEST XI LP | Director | Sell | — | — |
| 2025-09-09 | Warburg Pincus XI, L.P. | Director | Sell | — | — |
| 2025-09-09 | Warburg Pincus XI-C, LLC | Director | Sell | — | — |
| 2025-08-26 | Michael P Rutz | President of Sterigenics | Sell | — | — |
| 2025-08-07 | Jonathan M. Lyons | Sr. Vice President, CFO | F | — | — |
| 2025-05-27 | Christopher Simon | Director | A | — | — |
| 2025-05-27 | Ruoxi Chen | Director | A | — | — |
| 2025-05-27 | SEAN LAURENCE CUNNINGHAM | Director | A | — | — |
| 2025-05-27 | Ann R. Klee | Director | A | — | — |
| 2025-05-27 | CONSTANTINE S MIHAS | Director | A | — | — |
| 2025-05-27 | James Neary | Director | A | — | — |
| 2025-05-27 | VINCENT K PETRELLA | Director | A | — | — |
| 2025-05-27 | David E. Wheadon | Director | A | — | — |
| 2025-05-27 | Robert Brown Knauss | Director | A | — | — |
| 2025-05-27 | Karen Flynn | Director | A | — | — |
| 2025-03-04 | ALEXANDER DIMITRIEF | SVP, General Counsel and Sec. | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 88,822,952 | — |
| — | Director | 70,278,209 | — |
| — | Director | 34,102,952 | — |
| — | Director | 29,215,301 | — |
| — | Director | 19,102,952 | — |
| — | Director | 19,102,952 | — |
| — | Director | 12,735,301 | — |
| — | Executive Chairman | 4,367,305 | — |
| — | CFO and Treasurer | 738,649 | — |
| — | Chief Executive Officer | 375,939 | — |
| — | SVP, GC and Secretary | 358,590 | — |
| — | President of Sterigenics | 334,279 | — |
| — | Former SVP, GC and Sec. | 312,040 | — |
| — | Sr. Vice President, CFO | 217,304 | — |
| — | Director | 140,926 | — |
| — | Director | 95,751 | — |
| — | Director | 95,751 | — |
| — | Director | 95,751 | — |
| — | Director | 95,751 | — |
| — | Director | 89,882 | — |
| — | Director | 80,781 | — |
| — | Director | 61,649 | — |
| — | Director | 54,933 | — |
| — | Director | 54,191 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SHC quote page; the site-wide leaderboard is on the insider transactions hub.